MorphoSys AG (LTS:0NDV)
€ 66.8 0 (0%) Market Cap: 2.53 Bil Enterprise Value: 2.49 Bil PE Ratio: 0 PB Ratio: 51.57 GF Score: 45/100

MorphoSys AG at JPMorgan Healthcare Conference Transcript

Jan 12, 2022 / 10:15PM GMT
Release Date Price: €31.75 (-2.25%)
James Daniel Gordon
JPMorgan Chase & Co, Research Division - Senior Analyst

Good afternoon and good evening. I'm James Gordon, JPMorgan European Pharma and Biotech analyst. And today, at JPMorgan conference, I've got the pleasure of introducing the MorphoSys presentation and Q&A.

So we can have MorphoSys' CEO, Jean-Paul Kress, joining us at this 20-minute presentation, 20 minutes of Q&A afterwards and will be joined by the Board of management team.

And with that, I said, thanks a lot for joining us today, Jean-Paul, and looking forward to the presentation.

Jean;Paul Kress
MorphoSys AG - Chairman of Management Board, MD & CEO

Thank you, James. It's a pleasure to be here today to share our exciting progress and plans for the future.

On Slide 2, you can find our forward-looking statements before we begin on Slide 3.

At MorphoSys, we are working every day to bring new medicines and hope to people living with cancer. Our goal is to have a profound impact on the lives of cancer patients. We

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot